Preclinical applications: gastrointestinal research

Traditional preclinical tools struggle to combine biorelevance, robustness and throughput. The D-SIFR® technology addresses each of those points, so you don’t have to compromise anymore!

Pieter Van den Abbeele, CSO Cryptobiotix
  • Screen candidates for desired features
  • Characterise your ingredient & generate evidence during your product development cycle to move to the next step
  • Generate and protect your IP by identifying a set of significant features of your product
  • Support your claims with mechanistic information

A tailored preclinical approach for your research needs

Screening and in-depth characterisation of actives – Whether you are at an early R&D stage with no clear lead candidate or you need to generate robust data on the mechanism of action of your actives, Cryptobiotix’s technologies will address your research questions at the suitable depth. Allocate your budget wisely by screening candidates in a time- and cost-effective manner, before diving into your lead candidates with advanced analytics.

Always consider interindividual variability – Each individual’s gut microbiota has a unique signature and will interact with your products in different ways. Do not wait for the clinical trial and de-risk your product development by acknowledging and investigating the homogeneity or heterogeneity of this interplay early on. Do not use pooled faecal microbiota. Not only do you not need to anymore thanks to the throughput of the SIFR® technology, but you will also create a artificial community with excessively high taxonomic and functional diversity, not representative of any real-world individual.

Funnel showing the power of Cryptobiotix's preclinical screening and in-depth analysis of the mechanism of action prior to clinical studies.
Interindividual variability is a key element of gut microbiome studies and is often overlooked in preclinical studies.
Digestion and gut microbiome fermentation research.
Combine products to trigger synergies. Investigate dosing to optimise your formulation.

Innovate through synergies between products – Many one-ingredient products have been investigated over the past years. Aside of novel approaches and molecules, innovation comes from finding synergies in products combinations. As an example, synbiotics combine the best of prebiotics and probiotics or live biotherapeutic products (LBP). Or perhaps you can support the recovery of the microbiome by combining an active pharmaceutical ingredient (API) with some prebiotic fibres. A quick, meaningful SIFR® screening across combinations of actives will bring you a step further to your next lead candidate.

Optimal dosing – Which minimal dose of product would exert a significant impact on the microbiota? Or how to connect the preclinical dosing to the in vivo situation? The answer is not trivial, but we can help you with that as well.

Expertise in your field of research: functional foods & therapeutics

Prebiotics, HMO’s, polyphenols

Probiotics & synbiotics

Fortified beverages

API

LBP

FMT

A wide range of model organisms and health conditions

Human or animal – The D-SIFR® technology can be applied for human as well as monogastric animal simulations. Furthermore, physiological, microbiological and dietary components can be modulated to simulate various age groups, such as infants, toddlers or adults. Aside of the traditional ‘healthy’ population, the D-SIFR technology can be adapted to investigate a spectrum of dysbiotic and pathogenic conditions.

The D-SIFR simulates the digestion and gut microbiome interactions of various organisms: infants, toddlers, adults; diseased or healthy; cats, dogs, pigs and broiler.
Organisms modelled with the D-SIFR®


We changed the colour of this button so you can press it!